Diabetic kidney disease: From physiology to therapeutics

Journal of Physiology

Volumn 592, Issue 18, 2014, Pages 3997-4012

  Mora Fernández, Carmen ^a,b   Domínguez Pimentel, Virginia ^a   de Fuentes, Mercedes Muros ^a,b   Górriz, José L ^b,c   Martínez Castelao, Alberto ^b,d   Navarro González, Juan F ^a,b  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALISKIREN; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; AVOSENTAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; INSULIN; LISINOPRIL; LOSARTAN; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; RUBOXISTAURIN; SPIRONOLACTONE;

ACUTE KIDNEY FAILURE; ADD ON THERAPY; ALBUMINURIA; BLOOD FILTRATION; BLOOD PRESSURE REGULATION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EARLY DIAGNOSIS; END STAGE RENAL DISEASE; ENDOTHELIAL DYSFUNCTION; EXPERIMENTAL MODEL; GENETIC POLYMORPHISM; GENOTYPE ENVIRONMENT INTERACTION; GLOMERULAR FILTRATION BARRIER; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HEMODYNAMICS; HUMAN; HYPERKALEMIA; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BIOPSY; KIDNEY FAILURE; LIFESTYLE MODIFICATION; MACROALBUMINURIA; METABOLIC DISORDER; MICROALBUMINURIA; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PODOCYTE; POLYPHARMACY; PREVALENCE; PROTEIN EXPRESSION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SCREENING TEST; SMOKING CESSATION; TRANSGENIC ANIMAL; TREATMENT DURATION; ULTRAFILTRATION; UNSPECIFIED SIDE EFFECT; URINARY ALBUMIN EXCRETION; UROGENITAL SYSTEM PARAMETERS; VITAMIN D DEFICIENCY; ANIMAL; DIABETIC NEPHROPATHIES; KIDNEY; METABOLISM;

ALBUMINURIA; ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; KIDNEY;

EID: 84907874514     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2014.272328     Document Type: Review

References (92)

1. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS Group (2003). Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63, 225-232.
2. American Diabetes Association (2014). Standards of medical care in diabetes-2014. Diabetes Care 37 (Suppl. 1), S14-S80.
3. Andress DL, Coll B, Pritchett Y, Brennan J, Molitich M & Kohan DE (2012). Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD). Life Sci 91, 739-742.
4. Basu R, Lee J,Wang Z, Patel VB, Fan D, Das SK, Liu GC, John R, Scholey JW, Oudit GY & Kassiri Z (2012). Loss of TIMP3 selectively exacerbates diabetic nephropathy. Am J Physiol Renal Physiol 303, F1341-F1352.
5. Bennett WL, Maruthur NM, Singh S, Segal JB,Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB & Bolen S (2011). Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann InternMed 154, 602-613.
6. Bolton W, Cattran D,Williams M, Adler S, Appel G, Cartwright K, Foiles PG, Freedman B, Raskin P, Ratner R, Spinowitz B,Whittier F & Wuerth J; ACTION I Investigator Group (2004). Am J Nephrol 24, 32-40.
7. Bomback AS, Kshirsagar AV, Amamoo MA & Klemmer PJ (2008). Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 51, 199-211.
8. Burrows NR, Li Y & Geiss LS (2010). Incidence of treatment for end-stage renal disease among individuals with diabetes in the U.S. continues to decline. Diabetes Care 33, 73-77.
9. Chang WW, Zhang L, Yao YS, Su H, Jin YL & Chen Y (2013). Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and susceptibility to diabetic nephropathy in Chinese type 2 diabetic patients: a meta-analysis. Ren Fail 35, 1038-1043.
10. Cherney DZ, Konvalinka A, Zinman B, Diamandis EP, Soosaipillai A, Reich H, Lorraine J, Lai V, Scholey JW & Miller JA (2009). Effects of protein kinase Cß inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study. Diabetes Care 32, 91-93.
11. Coughlan MT, Forbes JM & Cooper ME (2007). Role of AGE crosslink breaker, alagebrium, as a renoprotective agent in diabetes. Kidney Int 72 (Suppl. 106), 54-60.
12. Cui W, Du B, ZhouW, Jia Y, Sun G, Sun J, Zhang D, Yuan H, Xu F, Lu X, Luo P & Miao L (2012). Relationship between five GLUT1 gene single nucleotide polymorphisms and diabetic nephropathy: a systematic review and meta-analysis. Mol Biol Rep 39, 8551-8558.
13. DCCT (1995). Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 47, 1703-1720.
14. DCCT (2000). Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Eng J Med 342, 381-389.
15. Dellamea BS, Pinto LC, Leitao CB, Santos KG & Canani LH (2014). Endothelial nitric oxide synthase gene polymorphisms and risk of diabetic nephropathy: a systematic review and meta-analysis. BMC Med Genet 15, 9.
16. De Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E & Andress D (2010). Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376, 1543-1551.
17. DiPetrillo K & Gesek FA (2004). Pentoxifylline ameliorates renal tumor necrosis factor expression, sodium retention, and renal hypertrophy in diabetic rats. Am J Nephrol 24, 352-359.
18. DuckworthW, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R,Warren SR, Goldman S, McCarren M, Vitek ME, HendersonWG & Huang GD; VADT Investigators (2009). Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360, 129-139.
19. Ewens KG, George RA, Sharma K, Ziyadeh FN & Spielman RS (2005). Assessment of 115 candidate genes for diabetic nephropathy by transmission/disequilibrium test. Diabetes 54, 3305-3318.
20. Fernández-Juárez G, Luño J, Barrio V, García de Vinuesa S, Praga M, Goicoechea M, Lahera V, Casas L & Oliva J; on behalf of the PRONEDI Study Group (2013). 25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system. Clin J Am Soc Nephrol 8, 1870-1876.
21. Flyvbjerg A, Denner L, Schrijvers BF, Tilton RG,Mogensen TH, Paludan SR & Rash R (2004). Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53, 166-172.
22. Forbes JM & Cooper ME (2013). Mechanisms of diabetic complications. Physiol Rev 93, 137-188.
23. Freedman BI,Wuerth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD & Spinowithz BS (1999). Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II). Control Clin Trials 20, 493-510.
24. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, DuckworthW, Leehey DJ, McCullough PA, O'Connor T, Palevsky PM, Reilly RF, Seliger S,Warren SR,Watnick S, Peduzzi P & Guarino P; for the VANEPHRON-D Investigators (2013). Combined angiotensin inhibition for the treatment of diabetic nephropathy. New Engl J Med 369, 1892-1903.
25. Gnudi L, Thomas SM & Viberti G (2007). Mechanical forces in diabetic kidney disease: a trigger for impaired glucose metabolism. J Am Soc Nephrol 18, 2226-2232.
26. Grahammer F, Schell C & Huber TB (2013). The podocyte slit diaphragm-from a thin grey line to a complex signalling hub. Nat Rev Nephrol 9, 587-598.
27. Guerrero-Romero F, Rodríguez-Morán M, Paniagua-Sierra J, García-Bulnes G, Salas-Ramírez M & Amato D (1995). Pentoxifylline reduces proteinuria in insulin-dependent and non-dependent diabetic patients. Clin Nephrol 43, 116-121.
28. Gunduz Z, Canoz O, Per H, Dusunsel R, Poyrazoglu H, Tez C & Saraymen R (2004). The effects of pentoxifylline on diabetic renal changes in streptozotocin-induced diabetes mellitus. Renal Fail 26, 597-605.
29. Halimi JM (2012). The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients. Diabetes Metab 38, 291-297.
30. Harmankaya O, Seber S & Yilmaz M (2003). Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail 25, 465-470.
31. Hasslacher C, Ritz E,Wahl P & Michael C (1989). Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 4, 859-863.
32. Hostetter TH, Troy JL & Brenner BM (1982). The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72, 375-380.
33. Huber TB & Benzing T (2005). The slit diaphragm: a signaling platform to regulate podocyte function. Curr Opin Nephrol Hypertens 14, 211-216.
34. Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, CushmanWC, Genuth S, Grimm RH Jr, Hamilton BP, Hoogwerf B, Karl D, Katz L, Krikorian A, O'Connor P, Pop-Busui R, Schubart U, Simmons D, Taylor H, Thomas A,Weiss D, Hramiak I; ACCORD trial group (2010). Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376, 419-430.
35. Kanwar YS, Sun L, Xie P, Liu F & Chen S (2011). A glimpse of various pathogenic mechanisms of diabetic nephropathy. Ann Rev Pathol 6, 395-423.
36. Kassiri Z,Oudit GY, KandalamV, Awad A, Wang X, Ziou X, Maeda N, Herzenberg AM & Scholey JW(2009). Loss of TIMP3 enhances interstitial nephritis and fibrosis. J Am Soc Nephrol 20, 1223-1235.
37. Kim MJ (2011). Oral cholecalciferol decreases albuminuria and urinary TGF-ß1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition. Kidney Int 80, 851-860.
38. Kohan DE, Pritchett Y, Molitch M,Wen S, Garimella T, Audhya P & Andress DL (2011). Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 22, 763-772.
39. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, Ritz E & Amann K (2004). 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 286, F526-F533.
40. Kunz R, Friedrich C,Wolbers M & Mann JF (2008). Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148, 30-48.
41. Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, PackhamDK & Lewis JB; Collaborative Study Group (2012). Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol 23, 131-136.
42. Lin Z, Huang G, Zhang J & Lin X (2014). Adiponectin gene polymorphisms and susceptibility to diabetic nephropathy: a meta-analysis. Ren Fail 36, 478-487.
43. Macía-Heras M, Del Castillo-Rodriguez N & Navarro-González J (2012). The renin-angiotensin-aldosterone system in renal and cardiovascular disease and the effects of its pharmacological blockade. J Diabetes Metab 3, 1-24.
44. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T & Viberti G; for the ASCEND Study Group (2010). Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 21, 527-535.
45. Mathieson PW (2012). The podocyte cytoskeleton in health and in disease. Clin Kidney J 5, 498-501.
46. Mehdi UF, Adams-Huet B, Raskin P, Vega GL & Toto RD (2009). Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 20, 2641-2650.
47. Mehrotra R, Kermah DA, Salusky IB,Wolf MS, Thadhani RI, Chiu YW,Martins D, Adler SG & Norris KC (2009). Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 76, 977-983
48. Miner JH (2011). Organogenesis of the kidney glomerulus: focus on the glomerular basement membrane. Organogenesis 7, 75-82.
49. Miner JH (2012). The glomerular basement membrane. Exp Cell Res 318, 973-978.
50. National Kidney Foundation (2007). KDOQI clinical practice guideline and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49 (Suppl. 2), S1-S180.
51. National Kidney Foundation (2012). KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60, 850-886.
52. Navarro JF, Milena FJ, Mora C, Le ón C & García J (2006). Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: Effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol 26, 562-570.
53. Navarro JF, Mora C, Muros M & García J (2005). Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short term, randomised, controlled trial. J Am Soc Nephrol 16, 2119-2126.
54. Navarro JF,Mora C,Muros M, Macía M & García J (2003). Effects of pentoxifylline administration on urinary N-acetyl-ß-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. Am J Kidney Dis 42, 264-270.
55. Navarro JF, Mora C, Rivero A, Gallego E, Chahin J, Macía M, Méndez ML & García J (1999). Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 33, 458-463.
56. Navarro-González JF & Mora-Fernández C (2008). The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19, 433-442.
57. Obeidat M & Ballermann BJ (2012). Glomerular endothelium: a porous sieve and formidable barrier. Exp Cell Res 318, 964-972.
58. Panichi V, De Pietro S, Andreini B, Bianchi AM, Migliori M, Taccola D, Giovannini L, Tetta C & Palla R (1998). Calcitriol modulates in vivo and in vitro cytokine production: A role for intracellular calcium. Kidney Int 54, 1463-1469.
59. Parving HH, Brenner BM,McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, Chatuverdi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P & Pfeffer MA; for the ALTITUDE Investigators (2012). Cardiorenal end points in a trial of aliskiren for type 2 diabetes. New Engl J Med 367, 2204-2213.
60. Parving HH, Persson F, Lewis JB, Lewis EJ & Hollenberg NK; AVOID Study Investigators (2008). Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358, 2433-2446.
61. Patel A, MacMahon S, Chalmers J, Neal B, Billot L,Woodward M,Marre M, Cooper M, Glasziou P,Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A,Williams B, Bompoint S, de Galan BE, Joshi R & Travert F; ADVANCE Collaborative Group (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358, 2560-2572.
62. Patterson CC, Gyürüs E, Rosenbauer J, Cinek O, Neu A, Schober E, Parslow RC, Joner G, Svensson J, Castell C, Bingley PJ, Schoenle E, Jarosz-Chobot P, Urbonaité B, Rothe U, Krzisnik C, Ionescu-Tirgoviste C,Weets I, Kocova M, Stipancic G, Samardzic M, de Beaufort CE, Green A, Dahlquist GG & Soltész G (2012). Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of non-uniformity over time in rates of increase. Diabetologia 55, 2142-2147.
63. Pavenstädt H, KrizW & Kretzler M (2003). Cell biology of the glomerular podocyte. Physiol Rev 83, 253-307.
64. Remuzzi G, Schieppati A & Ruggenenti P (2002). Nephropathy in patients with type 2 diabetes. New Engl J Med 346, 1145-1151.
65. Ritz E, Rychlik I, Locatelli F & Halimi S (1999). End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 34, 795-808.
66. Rivero A, Mora C, Muros M, García J, Herrera H & Navarro-González JF (2009). Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci 116, 479-492.
67. Satchell SC & Braet F (2009). Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol 296, F947-F956.
68. Schwarz U, Amann K, Orth SR, Simonaviciene A,Wessels S & Ritz E (1998). Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 53, 1696-1705.
69. Seok SJ, Lee ES, Kim GT, Hyun M, Lee JH, Chen S, Choi R, Kim HM, Lee EY & Chung CH (2013). Blockade of CCL2/CCR2 signalling ameliorates diabetic nephropathy in db/db mice. Nephrol Dial Transplant 28, 1700-1710.
70. Singh A, Satchell SC, Neal CR, McKenzie EA, Tooke JE & Mathieson PW (2007). Glomerular endothelial glycocalyx constitutes a barrier to protein permeability. J Am Soc Nephrol 18, 2885-2893.
71. Soler MJ,Wysocki J & Batlle D (2008). Angiotensin-converting enzyme 2 and the kidney. Exp Physiol 93, 549-556.
72. Stanton RC (2014). Clinical challenges in diagnosis and management of diabetic kidney disease. Am J Kidney Dis 63 (Suppl. 2), S3-S21.
73. Takamiya Y, Fukami K, Yamagishi S, Kaida Y, Nakayama Y, Obara N, Iwatani R, Ando R, Koike K, Matsui T, Nishino Y, Ueda S, Cooper ME & Okuda S (2013). Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice. Nephrol Dial Transplant 28, 55-62.
74. Takiishi T, Gysemans C, Bouillon R & Mathieu C (2010). Vitamin D and diabetes. Endocrinol Metab Clin North Am 39, 419-446.
75. Tervaert TWC, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Hass M, de Heer E, Joh K, Noël LH, Radhakrishnan J, Seshan S, Bajema IM & Bruijin JA; and on behalf of the Renal Pathology Society (2010). Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 21, 556-563.
76. Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, Haller H, Cooper ME & Forbes JM (2004). Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase Ca-dependent pathway. Diabetes 53, 2921-2930.
77. Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K & Anderson PW (2005). The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28, 2686-2690.
78. Tutle KR (2008). Protein kinase Cß inhibition for diabetic kidney disease. Diabetes Res Clin Pract 82 (Suppl. 1), S70-S74.
79. UK Prospective Diabetes Study Group (1998). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317, 703-713.
80. UKPDS (1998a). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 352, 837-853.
81. UKPDS (1998b). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854-865.
82. Wartiovaara J, Ofverstedt LG, Khoshnoodi J, Zhang J, Mäkelä E, Sandin S, Ruotsalainen V, Cheng RH, Jalanko H, Skoglund U & Tryggvason K (2004). Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J Clin Invest 114, 2004.
83. Weinbaum S, Tarbell JM & Damiano ER (2007). The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng 9, 121-167.
84. Whiting DR, Guariguata L,Weil C & Shaw J (2011). IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94, 311-321.
85. Yang S, Zhang J, Feng C & Huang C (2013). MTHFR 677T variant contributes to diabetic nephropathy risk in Caucasian individuals with type 2 diabetes: a meta-analysis. Metabolism 62, 586-594.
86. Yin YW, Qiao L, Sun QQ, Hu AM, Liu HL,Wang Q & Hou ZZ (2014). Influence of apolipoprotein E gene polymorphism on development of type 2 diabetes mellitus in Chinese Han population: a meta-analysis of 29 studies. Metabolism 63, 532-541.
87. Yu ZY, Chen LS, Zhang LC & Zhou TB (2012).Meta-analysis of the relationship between ACE I/D gene polymorphism and end-stage renal disease in patients with diabetic nephropathy. Nephrology (Carlton) 17, 480-487.
88. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J & Li YC (2008). Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase. Proc Natl Acad Sci U S A 105, 15896-15901.
89. Zhao Y, Yang J, Zhang L, Li Z, Yang Y, Tang Y & Fu P (2013). Association between TNF-α -308G/A polymorphism and diabetic nephropathy risk: a meta-analysis. Int Urol Nephrol 45, 1653-1659.
90. Zheng F, He C, CaiW,Hattori M, SteffesM & VlassaraH (2002). Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 18, 224-237.
91. Zhou TB, Jian ZP, Qin YH & Drummen GP (2014). Association of transforming growth factor-ß1 T869C gene polymorphism with diabetic nephropathy risk. Nephrology (Carlton) 19, 107-115.
92. Zhu JM,Wang B, Li J, Chen GM, Fan YG, Feng CC, Pan HF & Ye DQ (2013). D18S880 microsatellite polymorphism of carnosinase gene and diabetic nephropathy: a meta-analysis. Genet Test Mol Biomarkers 17, 289-294.